In this article, we will be taking a look at the 15 High Growth Mid-cap Stocks to Buy.
The US stock market is shifting as President Trump reinforces his “America First” agenda through subsidies and incentives aimed at boosting domestic manufacturing. Franklin Templeton’s Dina Ting notes that midcap stocks, which generate much of their revenue domestically, tend to benefit from this environment. She notes that growing interest in midcaps could divert investors away from crowded large-cap names, positioning midcaps as an attractive and previously overlooked growth opportunity.
In the past, mid-cap equities have outperformed their large-cap and small-cap counterparts in terms of returns. Although midcaps have behind large caps this year, Franklin Templeton points out that the S&P Mid-Cap 400 excelled on an annualized basis from 2000 to 2025. According to the company, this gap may present chances for active investors.
Hedge funds are showing signs of rotating out of large caps, according to a Reuters analysis published on November 15. The report highlights that several major hedge funds reduced exposure to mega-cap stocks in Q3 2025. Notably, Bridgewater Associates cut its holdings in two Magnificent Seven stocks by more than 50%, while increasing exposure to multiple mid-cap names.
Stocks
Our Methodology
For our methodology, we screened for stocks with market capitalizations between $2 billion and $10 billion and 5 years revenue growth of at least 30%. From this group, we selected the top 15 stocks and ranked them in ascending order based on the number of hedge fund holders as of Q3 2025, using data from the Insider Monkey database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Here is our list of the 15 high-growth mid-cap stocks to buy.
15. LifeStance Health Group, Inc. (NASDAQ:LFST)
Number of Hedge Fund Holders: 24
Market Capitalization: $2.82 billion
Revenue Growth (5Y): 36.75%
LifeStance Health Group, Inc. (NASDAQ:LFST) is among the high growth stock.
TheFly reported on January 8 that KeyBanc analyst Steve Dechert increased the price target for LFST from $6.50 to $8.50, keeping an Overweight rating on the stock. KeyBanc described this period as a possible “year of inflection” for several firms it watches, with changes to estimates and values showing indications of stabilizing, following a difficult year for HCIT shares. The firm warned that competition and regulatory considerations may continue to put pressure on valuation multiples, but it expects ongoing positive momentum throughout the majority of its coverage.
On the same day, Canaccord analyst Richard Close increased the price target for LifeStance Health Group, Inc. (NASDAQ:LFST) from $8.00 to $9.00, maintaining a Buy rating on the stock. The firm noted that LFST might be somewhat protected from more general industry uncertainty and updated its model to take opportunities within a changing healthcare environment into consideration. The expansion of in-network access to care was also emphasized as a benefit of favorable payer policies.
LifeStance Health Group, Inc. (NASDAQ:LFST) is a U.S.‑based provider of outpatient mental health services, offering both in‑person and virtual care to children, adolescents, adults, and older adults. The company’s multidisciplinary clinicians deliver psychiatric evaluations, therapy (individual, family, group), medication management, and psychological testing for conditions like anxiety, depression, bipolar disorder, and PTSD.
14. Veracyte, Inc. (NASDAQ:VCYT)
Number of Hedge Fund Holders: 25
Market Capitalization: $3.29 billion
Revenue Growth (5Y): 34.46%
Veracyte, Inc. (NASDAQ:VCYT) is one of the high growth stocks on our list.
TheFly reported on January 5 that Guggenheim analyst Subbu Nambi raised the price target for VCYT to $50 from $45, maintaining a Buy rating on the stock. The firm updated its models and forecasts for companies in the Diagnostics and Life Sciences Tools sector based on insights gained from recent management meetings.
Separately, on January 11, Veracyte, Inc. (NASDAQ:VCYT) released preliminary full-year 2025 results and 2026 guidance. It forecasts $570 million to $582 million in sales in 2026, which is higher than the consensus of roughly $565 million and shows sustained growth momentum.
Veracyte, Inc. (NASDAQ:VCYT) is a genomic diagnostics company that develops tests to improve diagnosis and treatment decisions for thyroid, lung, and other cancers, as well as autoimmune diseases, aiming to reduce unnecessary procedures and enhance patient care through precision medicine.
13. Kinsale Capital Group, Inc. (NYSE:KNSL)
Number of Hedge Fund Holders: 26
Market Capitalization: $9.28 billion
Revenue Growth (5Y): 34.25%
Kinsale Capital Group, Inc. (NYSE:KNSL) is one of the best high growth stocks.
TheFly reported on January 15 that Wells Fargo initiated coverage of KNSL with an Overweight rating and a $490 price target. The firm cited the company’s strong growth outlook, supported by new product launches and an expanding addressable market. According to Wells, KNSL is well-positioned to surpass its competitors, and investors will find the stock’s poor 2025 performance to be a compelling starting point.
In contrast, on January 14, Cantor Fitzgerald analyst Ryan Tunis lowered their price target on Kinsale Capital Group, Inc. (NYSE:KNSL) to $422 from $470 and maintained a Neutral rating on the shares. The analyst stated that, as near-term fundamentals are anticipated to decline before recovering, early enthusiasm for insurance brokers may have been premature. Although the industry is still enticing, short-term negative adjustments to consensus organic growth are anticipated.
Kinsale Capital Group, Inc. (NYSE:KNSL) is a U.S. specialty insurance company focused on the excess and surplus (E&S) lines market, underwriting complex or hard‑to‑place commercial property and casualty risks that standard insurers avoid. It operates nationwide through independent brokers, emphasizing disciplined underwriting, proprietary technology, and strong risk selection to drive consistent profitability and growth.
12. Palomar Holdings, Inc. (NASDAQ:PLMR)
Number of Hedge Fund Holders: 30
Market Capitalization: $3.40 billion
Revenue Growth (5Y): 37.08%
Palomar Holdings, Inc. (NASDAQ:PLMR) is among the best high growth stocks.
The Fly reported on January 7 that JPMorgan raised the PLMR price target to $155 from $145 while maintaining an Overweight rating. As part of its 2026 perspective, the firm revised its goals for the property and liability insurance industry. The analyst stated in his research note that although P&C fundamentals are getting worse, pricing, margin, and growth concerns seem to be mostly priced in.
Previously, on January 6, Keefe, Bruyette & Woods raised its price target on Palomar Holdings, Inc. (NASDAQ:PLMR) to $171 from $170 and reiterated an Outperform rating.
Palomar Holdings, Inc. (NASDAQ:PLMR) is a specialty insurance company focused on property and casualty products, including earthquake, inland marine, and excess and surplus lines. The company leverages data-driven underwriting and disciplined risk management to deliver profitable growth while serving niche markets underserved by traditional insurers.
11. Progyny, Inc. (NASDAQ:PGNY)
Number of Hedge Fund Holders: 31
Market Capitalization: $2.11 billion
Revenue Growth (5Y): 32.58%
The eleventh stock on our list is Progyny, Inc. (NASDAQ:PGNY).
TheFly reported on January 8 that Truist upgraded PGNY to Buy from Hold and raised its price target to $34 from $28. The firm stated that while worries about ProgynyRx are increasingly seen as a cash-pay versus covered-benefit issue rather than a structural issue, demand outside of Amazon is still strong. Additionally, Truist pointed out that the company’s cautious guidance strategy improves visibility and reduces the possibility of earnings surprises.
On the same day, KeyBanc analyst Scott Schoenhaus raised Progyny, Inc. (NASDAQ:PGNY)’s price target to $32 from $30 while maintaining an Overweight rating. The firm said that after a volatile year for healthcare IT stocks, many companies in its coverage are entering a period of fundamental inflection, with estimates stabilizing and valuations having largely bottomed. While KeyBanc expects momentum to persist, it also noted that competitive dynamics and regulatory factors could continue to weigh on valuation multiples.
Progyny, Inc. (NASDAQ:PGNY) specializes in managing fertility and family-building benefits for large employers. Its platform integrates clinical expertise with a “Smart Cycle” model, which focuses on achieving the best medical outcomes (such as single-birth pregnancies) while reducing overall healthcare costs for its clients.
10. Matador Resources Company (NYSE:MTDR)
Number of Hedge Fund Holders: 32
Market Capitalization: $5.32 billion
Revenue Growth (5Y): 34.60%
Matador Resources Company (NYSE:MTDR) is one of the best high growth stocks on our list.
TheFly reported on January 16 that Bank of America raised its price target on MTDR to $52 from $50 and reiterated a Buy rating. The firm continues to favor operators with strong asset bases and low breakeven costs, but it is still apprehensive about the oil market prognosis for 2026. Even in a more difficult commodity price environment, MTDR’s portfolio is positioned to fully finance dividends and capital expenditures, according to BofA.
In contrast, on January 13, RBC Capital Markets reduced its price target on Matador Resources Company (NYSE:MTDR) to $60 from $62 while maintaining an Outperform rating. The analyst pointed out that the change represents revised forecasts that consider final fourth-quarter commodities mark-to-market results and RBC’s modified commodity price assumptions, which predict lower oil prices throughout 2026 and 2027.
Matador Resources Company (NYSE:MTDR) is an independent U.S. energy firm that explores, develops, produces, and acquires oil and natural gas, primarily in the Delaware Basin, Wolfcamp, and Bone Spring plays. It also operates midstream services, including gas processing, transportation, and water infrastructure to support energy production and third-party customers.
9. PTC Therapeutics, Inc. (NASDAQ:PTCT)
Number of Hedge Fund Holders: 37
Market Capitalization: $5.82 billion
Revenue Growth (5Y): 37.78%
PTC Therapeutics, Inc. (NASDAQ:PTCT) is among the best high growth stocks.
TheFly reported on January 8 that Morgan Stanley raised its price target on PTCT to $90 from $78 and reiterated an Overweight rating. The analyst stated that while large-cap biopharma faces increasing pressure from impending patent expirations, the firm anticipates that U.S. small- to mid-cap biotechnology stocks will continue to outperform in 2026 as more commercial-stage companies generate sustainable cash flows.
Separately, PTC Therapeutics, Inc. (NASDAQ:PTCT) reported on January 12 that for full-year 2026, it expects total product revenue in the range of $700 million to $800 million, excluding Evrysdi royalty income and collaboration-related revenue. The business also projects GAAP R&D and SG&A expenses of $775 million to $815 million, while non-GAAP R&D and SG&A expenses are forecast between $680 million and $720 million, excluding approximately $95 million in non-cash stock-based compensation.
PTC Therapeutics, Inc. (NASDAQ:PTCT) is a global biopharmaceutical company that discovers, develops, and commercializes innovative medicines for rare genetic disorders. It focuses on transformational therapies, including small molecules and gene therapies, to improve health outcomes for patients with serious unmet needs worldwide.
8. Genius Sports Limited (NYSE:GENI)
Number of Hedge Fund Holders: 40
Market Capitalization: $2.36 billion
Revenue Growth (5Y): 34.07%
Genius Sports Limited (NYSE:GENI) is among the best high growth stocks.
TheFly reported on January 9, after Wells Fargo upgraded GENI to Overweight from Equal Weight and raised its price target to $16 from $13, the firm conducted a deeper review of the media and advertising opportunity presented at the company’s November Investor Day. It highlighted GENI’s NFL partnership as a key differentiator, citing the company’s ability to deliver live game viewership across multiple platform partners.
Wells Fargo sees potential upside beyond management’s long-term outlook and believes assumptions around direct NFL advertising and related brand opportunities may be conservative through 2028. The firm estimates Media revenue could reach approximately $350 million by 2028, compared with the company’s $300 million target, with the NFL contributing more than $50 million in self-serve advertising revenue.
Genius Sports Limited (NYSE:GENI) is a global sports data and technology company powering the sports, betting, and media ecosystem. It captures and distributes live sports data, streaming, analytics, and integrity services to leagues, sportsbooks, and broadcasters worldwide, enhancing fan engagement and commercial opportunities across major sports properties.
7. Alignment Healthcare, Inc. (NASDAQ:ALHC)
Number of Hedge Fund Holders: 40
Market Capitalization: $4.50 billion
Revenue Growth (5Y): 31.52%
The seventh stock on our list of high growth stocks is Alignment Healthcare, Inc. (NASDAQ:ALHC).
TheFly reported on January 16 that TD Cowen raised its price target on ALHC to $25 from $18.50 and maintained a Buy rating. The firm revised its model in response to information from a recent investor presentation and pointed out that Medicare Advantage enrollment is not anticipated to significantly surpass the estimated +20% growth rate and that FY2026 consensus EBITDA stays within the previous forecast range.
In addition, Alignment Healthcare, Inc. (NASDAQ:ALHC) revealed on January 12 that as of January 1, 2026, there were about 275,300 health plan subscribers, a 31% increase from the previous year. The organization offered recommendations for 290,000–296,000 members by the end of 2026. In order to stay within its full-year projection range, Alignment also anticipates consensus adjusted EBITDA of about $145 million in 2026.
Alignment Healthcare, Inc. (NASDAQ:ALHC) is a tech‑enabled U.S. Medicare Advantage company delivering personalized health plans and coordinated care for seniors and chronically ill members. It combines data‑driven clinical management and proprietary technology to improve outcomes, lower costs, and expand high‑quality Medicare Advantage services across multiple states.
6. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Number of Hedge Fund Holders: 40
Market Capitalization: $8.77 billion
Revenue Growth (5Y): 56.63%
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is among the best high growth stocks.
TheFly reported on January 13 that Piper Sandler lifted its price target on ARWR to $110 from $100, and reiterated an Overweight rating. The firm mentioned the new release of Redemplo for familial chylomicronemia syndrome, with more robust growth anticipated for FY27 and cautious sales projections for FY26. The analyst also voiced confidence regarding upcoming Phase III data in severe hypertriglyceridemia later in 2026, which would enable substantial label expansion.
Separately, on January 7, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that China’s NMPA approved Redemplo (plozasiran) to lower triglycerides in adults with familial chylomicronemia syndrome. This decision is the drug’s third regulatory clearance after clearances in the US and Canada. Sanofi will offer Redemplo in Greater China as part of an ongoing regional partnership, extending the therapy’s global reach.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a U.S. biopharmaceutical company developing RNA interference (RNAi)-based medicines that silence disease-causing genes. It targets rare and serious diseases with innovative therapies, including its first FDA-approved drug, and advances a broad pipeline through internal programs and strategic partnerships.
5. e.l.f. Beauty, Inc. (NYSE:ELF)
Number of Hedge Fund Holders: 43
Market Capitalization: $5.37 billion
Revenue Growth (5Y): 36.51%
The fifth stock on our list of high growth stocks is e.l.f Beauty, Inc. (NYSE:ELF)
TheFly reported on January 14 that UBS lowered its price target on ELF to $98 from $105 and maintained a Neutral rating on the stock. The analyst stated that although the company’s operating environment and market conditions are still difficult, fundamentals may improve in 2026.
Similarly, on the same day, Jefferies initiated coverage of e.l.f Beauty, Inc. (NYSE:ELF) with a Buy rating and a $110 price target. The analyst highlighted the company’s confidence in the continuous cosmetics cycle while revisiting the 2026 view with an emphasis on how consumer purchasing patterns might vary. According to the analyst, ELF is still the firm’s top choice in the industry.
e.l.f Beauty, Inc. (NYSE:ELF) is a U.S. cosmetics and skincare company known for affordable, clean, vegan, and cruelty‑free products sold globally. It operates multiple brands, including e.l.f. Cosmetics, e.l.f. Skin, Well People, Keys Soulcare, and Naturium, through retail and e‑commerce channels, are targeting broad consumer markets.
4. Shift4 Payments, Inc. (NYSE:FOUR)
Number of Hedge Fund Holders: 45
Market Capitalization: $5.71 billion
Revenue Growth (5Y): 38.61%
Shift4 Payments, Inc. (NYSE:FOUR) is among the best high growth stocks.
TheFly reported on January 15 that Deutsche Bank downgraded FOUR to Hold from Buy with a $65 price target. The firm expressed doubts about the long-term viability of FOUR’s organic expansion, pointing out that the company is growing riskier and more complicated, with less margin for error.
Similarly, on January 14, Seaport Research analyst Jeff Cantwell lowered the price target on Shift4 Payments, Inc. (NYSE:FOUR) to $89 from $100 and maintained a Buy rating on the stock. As part of its sector outlook for 2026, the firm revised its price goals and coverage of fintech. Seaport saw potential for a share price rebound over the course of the year and emphasized fair valuation multiples throughout the sector.
Shift4 Payments, Inc. (NYSE:FOUR) is a U.S. payment processing and commerce technology company providing omni‑channel payment acceptance, POS systems, and software solutions to merchants worldwide. It serves industries like hospitality, retail, and e‑commerce with secure, integrated platforms that support card, mobile wallet, QR, and analytics services.
3. Inspire Medical Systems, Inc. (NYSE:INSP)
Number of Hedge Fund Holders: 48
Market Capitalization: $2.68 billion
Revenue Growth (5Y): 55.76%
Inspire Medical Systems, Inc. (NYSE:INSP) stands third on our list.
TheFly reported on January 14 that Wells Fargo lowered its price target on INSP to $145 from $160 and maintained an Overweight rating on the shares. Although Wells pointed out possible short-term inconvenience, the business stated that it is still confident in handling reimbursement issues. The complete clarification may take some time, and updates are anticipated in the Q4 call.
Separately, on January 12, Inspire Medical Systems, Inc. (NYSE:INSP) reported strong preliminary results, projecting 2026 revenue of $1.003–$1.013 billion and Q4 revenue of $268.9–$269.1 million, both above consensus expectations.
Inspire Medical Systems, Inc. (NYSE:INSP) is a U.S. medical technology company that develops and commercializes minimally invasive neurostimulation solutions for patients with moderate to severe obstructive sleep apnea. Its flagship Inspire system improves airway function and quality of life for patients who cannot tolerate CPAP therapy. The company is headquartered in Minnesota.
2. UiPath, Inc. (NYSE:PATH)
Number of Hedge Fund Holders: 48
Market Capitalization: $7.67 billion
Revenue Growth (5Y): 32.68%
The second stock on our list of high growth stocks is UiPath, Inc. (NYSE:PATH)
TheFly reported on January 12 that Barclays raised its price target on PATH to $18 from $16 and maintained an Equal Weight rating. As part of its 2026 outlook, the firm revised its software sector ratings and price projections. Barclays noted a favorable background for software, with stable macro conditions and IT spending, appealing stock prices, and sector sentiment staying muted.
Separately, according to reports, on January 15, UiPath, Inc. (NYSE:PATH) saw mixed options activity, with shares down $0.12 near $15.24. Calls were slightly ahead of puts (put/call ratio 0.24), while volume was almost average. The put-call skew increased, indicating a need for downside protection, while implied volatility decreased but remained over the 52-week median.
UiPath, Inc. (NYSE:PATH) is a global software company and leader in agentic automation, providing AI‑enabled robotic process automation (RPA) and workflow orchestration technology that helps enterprises automate complex business processes.
1. Chord Energy Corporation (NASDAQ:CHRD)
Number of Hedge Fund Holders: 49
Market Capitalization: $5.25 billion
Revenue Growth (5Y): 31.29%
Chord Energy Corporation (NASDAQ:CHRD) tops our list for being one of the best high growth stocks.
TheFly reported on January 17 that Jefferies lowered its price target on CHRD to $99 from $104 and maintained a Hold rating on the shares as part of a Q4 earnings preview. As new drilling projects increase, the firm anticipates that its capital efficiency will progressively improve, potentially outperforming consensus capital expenditure predictions for 2026.
Similarly, a day before, on January 16, Scotiabank analyst Paul Cheng lowered the price target on Chord Energy Corporation (NASDAQ:CHRD) to $114 from $120 and maintained a Sector Perform rating. The firm updated its coverage of U.S. refining, integrated oil, and E&P equities. In the future, Scotiabank anticipates that investors will keep an eye on 2026 guidance and determine whether revisions to capital plans or cost-management actions would be prompted by broader market conditions.
Chord Energy Corporation (NASDAQ:CHRD) is an independent U.S. oil and gas exploration and production company focused on acquiring, developing, and producing crude oil, natural gas, and natural gas liquids in the Williston Basin. It is headquartered in Houston and delivers energy resources, drives value creation, and returns capital to shareholders through disciplined operations.
While we acknowledge the potential of CHRD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CHRD and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
